Ruffer’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-24,567
Closed -$5.91M – 206
2026
Q2
$5.91M Buy
+24,567
New +$5.38M 0.21% 88
2026
Q1
– Sell
-14,242
Closed -$2.42M – 211
2025
Q4
$2.42M Buy
+14,242
New +$2.18M 0.11% 119
2025
Q1
– Sell
-58,767
Closed -$7.24M – 113
2024
Q4
$7.24M Buy
+58,767
New +$6.93M 0.26% 51
2024
Q2
– Sell
-7,702
Closed -$927K – 58
2024
Q1
$927K Hold
7,702
– – 0.04% 52
2023
Q4
$947K Hold
7,702
– – 0.04% 60
2023
Q3
$1.01M Hold
7,702
– – 0.06% 58
2023
Q2
$955K Hold
7,702
– – 0.06% 57
2023
Q1
$1.13M Hold
7,702
– – 0.04% 70
2022
Q4
$1.23M Hold
7,702
– – 0.08% 61
2022
Q3
$1.07M Hold
7,702
– – 0.07% 72
2022
Q2
$1.2M Hold
7,702
– – 0.05% 69
2022
Q1
$1.2M Hold
7,702
– – 0.03% 77
2021
Q4
$1.01M Hold
7,702
– – 0.02% 76
2021
Q3
$996K Hold
7,702
– – 0.03% 68
2021
Q2
$1.37M Buy
+7,702
New +$1.33M 0.04% 61

Other funds holding JAZZ

Ruffer's JAZZ Position: Q3 2026 in Review

Ruffer sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2026, closing a stake of 24,567 shares — an estimated $5.91M sold.

Ruffer first reported a position in JAZZ in Q2 2021 and held it in 15 quarters. The position peaked at $7.24M in Q4 2024. 538 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Ruffer reported no remaining Jazz Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ruffer sold 24,567 Jazz Pharmaceuticals shares in Q3 2026, an estimated $5.91M.
  • Ruffer first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 15 quarters.
  • Ruffer's Jazz Pharmaceuticals position peaked at $7.24M in Q4 2024.
  • 538 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Ruffer's 13F filing for Q3 2026, filed 10 Nov 2026.